All Time (46 Recipes)
Past 24 Hours
Submit Your Post
5 hours ago Breastcancer.org Show details
Perjeta targets a different area on the HER2 receptor than Herceptin does, so it’s believed to work in a way that is complementary to Herceptin. Tykerb …
Category: Faq RecipesShow more
9 hours ago Perjeta.com Show details
What does PERJETA treat? PERJETA ® (pertuzumab) is a prescription medicine approved for use in combination with Herceptin ® (trastuzumab) and chemotherapy for:. use prior to surgery (neoadjuvant treatment) in people with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive).
1 hours ago Perjeta.com Show details
8 hours ago Perjeta.com Show details
PERJETA ® (pertuzumab) is a prescription medicine approved for use in combination with Herceptin ® (trastuzumab) and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.
Metastatic breast cancer treatment. PERJETA, along with Herceptin ® (trastuzumab) and docetaxel, is a first-line treatment for HER2+ breast cancer that has spread to other parts of the body (metastasized). This will be given to you if you have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer (first line).
9 hours ago Curetoday.com Show details
He said the Perjeta -containing regimen reduced the risk of developing invasive breast cancer by 19 percent. After a median follow-up of 45.4 months, 7.1 percent (171 patients) in the Perjeta group had developed invasive breast cancer, compared with …
4 hours ago Perjeta.com Show details
The Perjeta -containing regimen reduced the risk of developing invasive breast cancer by 19 percent. After a median follow-up of 45.4 months, 7.1 percent (171 patients) in the Perjeta group had developed invasive breast cancer, compared with 8.7 …
9 hours ago Breastcancer.org Show details
HER2-positive breast cancers have too many copies of the HER2/neu gene, which make too much of the HER2 protein. HER2-positive breast cancers tend to be more aggressive than cancers that are HER2-negative. Both Herceptin and Perjeta work against HER2-positive breast cancers by blocking the cancer cells' ability to receive growth signals.
2 hours ago Curetoday.com Show details
Perjeta inhibits cancer growth in HER2 positive cases. Used in conjunction with Herceptin, it’s a powerful one-two punch against breast cancer cells and inhibits growth. The final bag that my wife was receiving was the chemo, or Taxol. This is the stuff that causes you to lose your hair, eyebrows, eyelashes.
3 hours ago Breastcancernow.org Show details
Pertuzumab is a targeted or biological therapy drug. Pertuzumab is the non-branded name of the drug. Its brand name is Perjeta. When pertuzumab is combined with the drug trastuzumab in an injection its brand name is Phesgo. Targeted therapies block the growth and spread of cancer.
4 hours ago Chemoexperts.com Show details
Each of the medications in THP is designed to kill cancer cells or slow growth of cancer cells. T – Taxotere® (Docetaxel) H – Herceptin® (Trastuzumab) P – Perjeta® (Pertuzumab) Goals of therapy: THP is given to shrink tumors and slow the progression of the disease, which can decrease symptoms of breast cancer and possibly extend life.
3 hours ago Breastcancer.org Show details
The study showed that women diagnosed with metastatic, HER2-positive breast cancer who were treated with a combination of Perjeta, Herceptin, and Taxotere lived 6 months longer without the cancer growing (progression-free survival) compared to women treated with only Herceptin and Taxotere. On June 21, 2012, Genentech, the company that makes
Perjeta targets a different area on the HER2 receptor than Herceptin does, so it’s believed to work in a way that is complementary to Herceptin. By blocking the signals, Perjeta can slow or stop the growth of the breast cancer. Perjeta and Herceptin are …
Just Now Healwithfood.org Show details
This recipe collection includes over 50 healthy recipes that call for foods rich in breast cancer fighting nutrients. In addition to containing anti-breast cancer nutrients and phytochemicals such as allicin, vitamin C, indoles, ellagic acid, beta-carotene, zinc and vitamin E, the recipes included in this collection tend to have a low glycemic
Category: Healthy RecipesShow more
3 hours ago Mybcteam.com Show details
Perjeta (Pertuzumab) for Breast Cancer. Perjeta is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic breast cancer in cases where tumors overexpress the HER2 protein and chemotherapy or anti-HER2 therapy has not been tried. Perjeta was also approved by the FDA for neoadjuvant (presurgery) treatment
Category: Tea RecipesShow more
1 hours ago Inspire.com Show details
hi have breast cancer primary and spread to liver and lungs ,i am now on perjeta and herceptin and wondered if anyone else suffers from permanebt diarrhoea,i am now taking immodium and codeine but does not appear to help ,plus do you ladies have any other symptoms to share while on this treatment. thanks jazmia
4 hours ago Medicalxpress.com Show details
(HealthDay) -- Perjeta (pertuzumab) has been approved by the U.S. Food and Drug Administration to treat people with HER2-positive late-stage breast cancer, the agency said in …
2 hours ago Navigatingcare.com Show details
I go in for my first Herceptin and Perjeta only treatment next week and I am hoping I feel good. My hair is slowly growing back but my nails are not so hot, I keep them very short and painted. I started do light work outs to gain back some energy and strength and it has been a …
4 hours ago Food.ndtv.com Show details
Data released by the pharmaceutical company Roche suggests Perjeta could, in combination with other drugs, increase the survival of women with advanced breast cancer by 15 months. The results will raise the stakes in the battle in the UK over the funding of cancer drugs.
5 hours ago Hickeysolution.com Show details
Perjeta is a drug indicated to treat HER-2 positive breast cancer that has spread to other organs and tissues (metastasis). To be treated with this drug, the patient must not have received any previous anti-HER-2 treatment or chemotherapy against metastatic tumors. Changing 4 habits can reduce up to 20,000 cancer cases.
4 hours ago Canceractive.com Show details
This patient-friendly article is about chemotherapy drug, Perjeta or Pertuzumab approved by the FDA in 2012 as a cancer drug in the treatment of HER2-positive metastatic breast cancer. Pharmaceutical company Roche has clinched European approval for its breast cancer drug Perjeta, fuelling the company’s hopes that the drug will become the standard of care for an aggressive, …
3 hours ago Inspire.com Show details
1 hours ago Curetoday.com Show details
Breast cancer specialist Mark Pegram discusses recent breast cancer studies and what's to come for patients with HER2-positive breast cancer. In 2013, Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy became the first neoadjuvant regimen formally approved by the Food and Drug Administration (FDA) for the
1 hours ago Breastcancernow.org Show details
“A further rejection of Perjeta is a devastating blow to higher risk women desperate for a positive and swift final decision that could help them enjoy a breast cancer free future. “Many women today will be left grappling with uncertainty and overwhelming fear of their breast cancer returning.
6 hours ago Cancertreatments.co.nz Show details
1 This booklet is for people who have HER2-positive breast cancer that has spread to other areas of their body. This is known as advanced breast cancer, metastatic breast cancer or secondary breast cancer. All these different terms can be confusing, so we will call it …
3 hours ago Theguardian.com Show details
Data released by the pharmaceutical company Roche suggests Perjeta could, in combination with other drugs, increase the survival of women with …
9 hours ago Cancer.cankado.com Show details
Perjeta is a cancer medicine for treating adults with ‘HER2-positive’ breast cancer (where a protein called HER2 is found on the cancer cells). Perjeta is used in the following situations: treatment of metastatic breast cancer (cancer that has spread to other parts of the body) that has not already been treated with chemotherapy medicines
NICE has published draft guidance to not recommend Perjeta (pertuzumab) for routine NHS use after surgery for some higher risk breast cancer.. In summary of their decision, NICE stated: 'The committee concluded that current research showed only a small difference in the proportion of people who remained free from invasive disease, and this effect was itself uncertain.'
4 hours ago Drugs.com Show details
Perjeta is a cancer medication that interferes with the growth and spread of cancer cells in the body. Perjeta is used together with other cancer medicines (trastuzumab and docetaxel) to treat HER2-positive breast cancer. Perjeta may also be used for purposes not listed in this medication guide. Warnings. Perjeta can cause birth defects or
9 hours ago Webmd.com Show details
June 12, 2012 -- The FDA on Monday approved a new drug for the treatment of a type of late-stage breast cancer.The drug helped stop cancer …
5 hours ago Medicinenet.com Show details
HER2 is a protein involved in cell growth. Increased amounts of the protein, which tend to fuel cancer cell growth and survival, are found in about 20 percent of breast cancer cases, the FDA said. Perjeta was approved for people who haven't been previously treated with an anti-HER2 therapy for metastatic (spreading) breast cancer, the agency said.
5 hours ago Blog.canceractive.com Show details
Roche aims to combine Perjeta with its older drug Herceptin, the company’s second-biggest seller, for women with a form of cancer known as HER2-positive, which makes up about a quarter of all breast cancers and has no cure. U.S. health regulators approved the drug last June and Perjeta won initial backing from European authorities in December.
1 hours ago Theguardian.com Show details
Perjeta, the brand name of pertuzumab, could be helpful in the treatment of 1,400 women a year who develop a particularly aggressive form of breast cancer, but …
Category: Rice RecipesShow more
6 hours ago Cbsnews.com Show details
The Food and Drug Administration (FDA) approved Perjeta for women with a form of early-stage breast cancer who face a high risk of having their cancer spread to other parts of the body.
4 hours ago Breastcancer-news.com Show details
Health Canada has approved the use of Perjeta in combination with Herceptin (trastuzumab) and chemotherapy to prevent the recurrence of early breast cancer after surgery.. The combination is meant for women with HER2-positive early breast cancer who have traces of cancer in their lymph nodes and/or have hormone negative disease.
8 hours ago Curetoday.com Show details
Perjeta was initially approved for use in combination with Herceptin and docetaxel as a neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer. Although much success has been seen, 15 percent of patients with HER2-positive breast cancer will recur.
4 hours ago Practiceupdate.com Show details
Roche/Genentech Inc. will launch its new HER2-positive breast cancer drug Perjeta (pertuzumab) at a 31% premium to the price of its existing gold standard Herceptin (trastuzumab), an aggressive strategy that will substantially increase the cost of treating patients with metastatic HER2-positive breast cancer – especially because Perjeta is to be given in conjunction with Herceptin.
Just Now Chemocare.com Show details
Pertuzumab is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. This medication is classified as an "antineoplastic agent and a monoclonal antibody". (For more detail, see “How Pertuzumab Works” below).
4 hours ago Thesocialmedwork.com Show details
Perjeta (pertuzumab) is indicated for the treatment of HER2 positive breast cancer in patients with metastatic cancer or as neoadjuvant treatment for patients with locally advanced, inflammatory, or early stage breast cancer as part of a complete treatment regimen for early breast cancer 1,2,3. How does Perjeta (pertuzumab) work?
7 hours ago Breast-cancer.emedtv.com Show details
The primary use of Perjeta is to treat breast cancer. It is approved only for adults and in combination with certain other medications. This medicine is specifically designed to treat certain forms of breast cancer that have spread to other areas and have certain receptors on the cancer cells.
Just Now Breastlink.com Show details
Adding Perjeta to the Treatment of HER2-Positive Tumors Prior to Surgery. Pertuzumab (Perjeta) became the first drug to ever be approved by the FDA for use prior to surgery for non-metastatic breast cancer on September 30, 2013. This development further signals a paradigm shift away from chemotherapy and towards targeted therapy
7 hours ago Bbc.co.uk Show details
Life-extending drug Perjeta approved for secondary breast cancer. A drug used to treat advanced breast cancer has been approved for use on the NHS in …
7 hours ago Europeanpharmaceuticalreview.com Show details
The Perjeta regimen is the first neoadjuvant breast cancer treatment approved by the EC based on pathological complete response (pCR) data. Every year in Europe nearly 100,000 people are diagnosed with HER2-positive breast cancer, an aggressive type of the disease that is more likely to progress than HER2-negative cancer.
7 hours ago Webmd.com Show details
The addition of Herceptin also boosted 10-year overall survival rates from 75 percent to 84 percent. And the 10-year disease-free survival rate went from 62 percent to 74 percent for those also
9 hours ago Pharmaphorum.com Show details
Perjeta has previously been recommended by NICE for NHS use in treating early HER2-positive breast cancer before surgery, i.e. neo-adjuvant …
All Time (46 Recipes)
Past 24 Hours
Perjeta Boosts Overall Survival in HER2-Positive Metastatic Breast Cancer. Metastatic breast cancer is cancer that has spread to parts of the body away from the breast, such as the bones or liver. The FDA approval was based on results from the CLEOPATRA (Clinical Evaluation Of Pertuzumab And TRAstuzumab) study.
Perjeta also is approved: to be used in combination with Herceptin and Taxotere before surgery to treat HER2-positive, early-stage (the cancer must be larger than 2 cm or cancer must be in the lymph nodes), inflammatory, or locally advanced-stage breast cancer with a high risk of metastasizing or becoming fatal.
For the treatment of HER2+ metastatic breast cancer, you will receive Perjeta and Herceptin until the medicine no longer controls your breast cancer or you have side effects that require you to stop treatment. You may receive other treatments with these medications.
The most common side effects of PERJETA when given with Herceptin and chemotherapy as part of an early breast cancer regimen after surgery are: The most common side effects of PERJETA when given with Herceptin and docetaxel for treatment of breast cancer that has spread to other parts of the body (metastatic) are: